BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Bigger Picture Talks at CEB with Constantin Coussios: Engineering 
 Tomorrow's Cancer Therapies - Professor Constantin Coussios\, Director of 
 the Oxford Institute of Biomedical Engineering
DTSTART:20221123T160000Z
DTEND:20221123T170000Z
UID:TALK192878@talks.cam.ac.uk
CONTACT:Ellie Hall
DESCRIPTION:"Get your free tickets on Eventbrite":https://www.eventbrite.c
 o.uk/e/engineering-tomorrows-cancer-therapies-tickets-463588765477\n\nOur 
 departmental seminar series\, Bigger Picture Talks\, runs throughout the a
 cademic year\, inviting thought-leaders from across the world driving sign
 ificant advances in our impact areas of energy\, health and sustainability
  to share and discuss their work with us.\n\nAbstract: Tumour physiology p
 resents a formidable barrier to the delivery of current and emerging antic
 ancer therapeutics\, including antibodies\, oncolytic viruses\, antibody-d
 rug conjugates and mNRA. Furthermore\, potent next-generation immunotherap
 ies can be transformative\, but for reasons that remain poorly understood 
 are only highly effective in less than a fifth of cancer patients.\n\nTher
 mal and mechanical effects associated with extracorporeal stimuli\, such a
 s ultrasound\, have a major role to play in enabling therapeutics to overc
 ome the elevated intratumoural pressure\, sparse vascularity and dense ext
 racellular matrix encountered in the majority of solid tumours\, in order 
 to achieve better intratumoural distribution and therapeutic efficacy. In 
 recent pre-clinical studies\, these effects have also been shown to be abl
 e to mediate significantly enhanced innate and adaptive immune responses.\
 n\nAn overview of the stimulus-responsive nanotechnologies that have been 
 recently tested clinically or are currently at an advanced stage of pre-cl
 inical development will be provided. These include thermosensitive liposom
 es\, which recently completed a first-in-man trial of remotely activated o
 ncological drug delivery (TarDox\, Lancet Oncology 2018)\; gas-stabilizing
  solid polymeric particles\, currently ongoing a first-in-human trial (CEe
 DD)\; and next generation protein-based particles\, which are being specif
 ically engineered to awaken the immune system.\n\nChallenges in the pre-cl
 inical development\, scale-up and pre-clinical testing of these potentiall
 y transformative stimulus-responsive technologies will be discussed\, alon
 gside a novel method of accelerating their clinical translation using isol
 ated normothermically perfused human organs to predict their pharmacokinet
 ics and pharmacodynamics ahead of human trials.\n\nBio: Professor Const
 antin Coussios (MEng\, PhD Cantab.) is the Director of the Oxford Institut
 e of Biomedical Engineering and was elected to the first statutory chair i
 n Biomedical Engineering at the University of Oxford in 2011. He was the r
 ecipient of the 2017 Silver Medal of the UK’s Royal Academy of Engineeri
 ng for his contributions to the translation of novel medical technologies 
 into clinical practice. In 2008\, he co-founded OrganOx Ltd.\, which devel
 oped the world’s first normothermic liver perfusion device for improved 
 organ preservation prior to transplantation (Nature 2018). In 2014\, he wa
 s the lead academic founder of OxSonics Ltd.\, which exploits nanobubbles 
 and ultrasound to enhance drug delivery to tumours (Lancet Oncology 2018).
  In 2016\, he co-founded OrthoSon Ltd.\, which is developing a new minimal
 ly invasive technique for repair and replacement of the intervertebral dis
 c. In 2019\, he was elected a Fellow of the Royal Academy of Engineering a
 nd in 2022 was awarded an OBE for services to Biomedical Engineering.
LOCATION:Lecture Theatre 2\, Department of Chemical Engineering and Biotec
 hnology\, West Cambridge Site
END:VEVENT
END:VCALENDAR